OPEN CFDA 93.847 ↗ Competitive Cooperative Agreement Competitive ~100h typical effort

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

🏛 National Institutes of Health (HHS-NIH11)

✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026

⏰ Deadline
Oct 9, 2026 in 84 days
🎯 Expected awards
3 recipients
📅 Fiscal Year
FY 2027
📍 Scope
National

Can you apply?

This grant supports research on anti-obesity medication (AOM) treatment strategies in children and adolescents. Research institutions, universities, and medical centers with clinical research capacity can apply. Applicants must have institutional review board (IRB) approval and clinical infrastructure to conduct pediatric studies. This is a clinical research grant, not direct service funding.

Eligible applicants
Check your eligibility — what type of organization are you?

Not the right fit? Find grants for your organization in 5 questions →

Key dates

  1. Jun 8, 2026 Applications open
  2. Oct 9, 2026 Application deadline in 84 days
  3. Jul 1, 2027 Award announced
  4. Jul 1, 2027 Project start

Program description

This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs.  Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The consortium may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts.   

Who can apply

Eligible applicants

Demographic focus

How to apply

Application links

Key dates & requirements

  • 📅 Expected award date: Jul 1, 2027
  • 🚀 Project start date: Jul 1, 2027

Required documents

  • SF-424 (Application for Federal Assistance)
  • Project Narrative/Research Plan
  • Budget and Budget Justification
  • Biographical Sketches of Key Personnel
  • Institutional Review Board (IRB) Approval or Plan
  • Letters of Support from Clinical Sites
  • Data Safety Monitoring Plan
  • Human Subjects Research Compliance Documentation

Program contact

Funding track record

Recent awards under CFDA 93.847 from the last 3 years — real organizations that won funding through this same program.

47
awards (3 yrs)
$2.1B
total funded
29
unique recipients
$43.8M
average award

Top 10 Largest Recent Awards

  1. $438,527,853
  2. $200,221,259
  3. $152,979,352
  4. $112,529,392
  5. $66,521,567
  6. $45,186,589
  7. $39,699,167
  8. $37,490,770
  9. $34,242,949
  10. $31,624,784

Top States by Funding

  • WA 3 awards $492.3M
  • NC 4 awards $291.6M
  • FL 2 awards $184.1M
  • MA 6 awards $168.4M
  • PA 6 awards $168.1M

Source: USAspending.gov — federal spending transparency. Data covers last 3 years.

Funding history

Annual funding for this program — Federal obligations (CFDA 93.847). How funding has trended year over year.

2024 $1,971,472,000
2025 $2,043,166,000
2026 est. $111,289,000

FAQ

Who can apply for this grant?

Research institutions, medical centers, universities, and teaching hospitals with pediatric clinical research infrastructure and IRB approval capacity.

What types of activities does this grant support?

Clinical research on anti-obesity medication effectiveness, safety, and optimal treatment strategies for children and adolescents.

What is the typical funding range?

NIH research grants vary widely, typically ranging from $150K to $500K+ annually, depending on project scope and complexity.

How competitive is this grant?

NIH grants are highly competitive. Strong preliminary data, experienced research teams, and rigorous study designs significantly improve success rates.

When are applications due?

Specific deadline dates vary by funding cycle. Check NIH.gov for your program's exact submission deadline.

💡 Tips for applicants

  • Demonstrate existing clinical infrastructure and capacity for pediatric research and patient recruitment.
  • Include strong preliminary data on AOM outcomes in your target pediatric population.
  • Build a multidisciplinary team with pediatric endocrinologists, cardiologists, and mental health specialists.
  • Design rigorous study protocols with clear measurable endpoints for medication efficacy and safety.
  • Align your study design with current NIH priorities in childhood obesity prevention and treatment.

⚠️ Common mistakes

Weak preliminary data or unclear clinical significance of the proposed treatment approach. Insufficient detail on patient recruitment and retention strategies for pediatric populations. Lack of adequate safety monitoring protocols for medication use in children.

Similar grants

Source: Grants.gov · FY 2027 · Last updated Jun 8, 2026

84 days left Oct 9, 2026
Apply →